Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.
Bearz A, Martini JF, Jassem J, Kim SW, Chang GC, Shaw AT, Shepard DA, Dall'O' E, Polli A, Thurm H, Zalcman G, Garcia Campelo MR, Penkov K, Hayashi H, Solomon BJ. Bearz A, et al. Among authors: penkov k. J Thorac Oncol. 2023 Nov;18(11):1581-1593. doi: 10.1016/j.jtho.2023.07.023. Epub 2023 Aug 3. J Thorac Oncol. 2023. PMID: 37541389 Free article.
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. Makharadze T, et al. Among authors: penkov k. J Thorac Oncol. 2023 Jun;18(6):755-768. doi: 10.1016/j.jtho.2023.03.008. Epub 2023 Mar 29. J Thorac Oncol. 2023. PMID: 37001859 Free article. Clinical Trial.
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3.
Makharadze T, Quek RGW, Melkadze T, Gogishvili M, Ivanescu C, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Konidaris G, Rietschel P, Gullo G. Makharadze T, et al. Among authors: penkov k. Cancer. 2023 Jul 15;129(14):2256-2265. doi: 10.1002/cncr.34687. Epub 2023 May 8. Cancer. 2023. PMID: 37151113 Free article. Clinical Trial.
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Chi KN, et al. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23. J Clin Oncol. 2023. PMID: 36952634 Free PMC article. Clinical Trial.
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.
Cho BC, Penkov K, Bondarenko I, Kurochkin A, Pikiel J, Ahn HK, Korożan ME, Osipov M, Odintsova S, Braiteh F, Ribas A, Grilley-Olson JE, Lugowska I, Bonato V, Damore MA, Yang W, Jacobs IA, Bowers M, Li M, Johnson ML. Cho BC, et al. Among authors: penkov k. ESMO Open. 2023 Aug;8(4):101589. doi: 10.1016/j.esmoop.2023.101589. Epub 2023 Jun 27. ESMO Open. 2023. PMID: 37385154 Free PMC article. Clinical Trial.
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
Haanen JBAG, Larkin J, Choueiri TK, Albiges L, Rini BI, Atkins MB, Schmidinger M, Penkov K, Michelon E, Wang J, Mariani M, di Pietro A, Motzer RJ. Haanen JBAG, et al. Among authors: penkov k. ESMO Open. 2023 Jun;8(3):101210. doi: 10.1016/j.esmoop.2023.101210. Epub 2023 Apr 25. ESMO Open. 2023. PMID: 37104931 Free PMC article.
Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10).
Siefker-Radtke AO, Huddart RA, Bilen MA, Balar A, Castellano D, Sridhar SS, De Giorgi U, Penkov K, Vasiliev A, Peer A, Järvinen R, Harputluoğlu H, Koshkin VS, Poushnejad S, Wang T, Qureshi A, Tagliaferri MA, Zalevsky J, Loriot Y. Siefker-Radtke AO, et al. Among authors: penkov k. Urol Oncol. 2024 Oct 29:S1078-1439(24)00671-9. doi: 10.1016/j.urolonc.2024.09.030. Online ahead of print. Urol Oncol. 2024. PMID: 39477771
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study.
Dudnichenko O, Penkov K, McKean M, Mandalà M, Kukushkina M, Panella T, Csőszi T, Gerletti P, Thakur M, Polli A, di Pietro A, Schadendorf D. Dudnichenko O, et al. Among authors: penkov k. Eur J Cancer. 2024 Oct 11;213:115070. doi: 10.1016/j.ejca.2024.115070. Online ahead of print. Eur J Cancer. 2024. PMID: 39427441 Free article.
Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies.
Penkov K, Bondarenko I, Saenko DV, Kulyaba Y, Guo J, Gong Y, Yamamoto N, Hotko YS, Boyko V, Fadeeva NV, Ursol GM, Ahn HK, Kislov NV, Shen CI, Davis C, Kowalski K, Michelon E, Pavlov D, Hirohashi T, Cho BC. Penkov K, et al. Ther Adv Med Oncol. 2024 Sep 11;16:17588359241274592. doi: 10.1177/17588359241274592. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39281971 Free PMC article.
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09).
Tannir NM, Formiga MN, Penkov K, Kislov N, Vasiliev A, Gunnar Skare N, Hong W, Dai S, Tang L, Qureshi A, Zalevsky J, Tagliaferri MA, George D, Agarwal N, Pal S. Tannir NM, et al. Among authors: penkov k. J Clin Oncol. 2024 Aug 10;42(23):2800-2811. doi: 10.1200/JCO.23.02082. Epub 2024 Jun 5. J Clin Oncol. 2024. PMID: 38838287 Clinical Trial.
26 results